Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
27 June 2024 - 10:00PM
Business Wire
Cellares, the first Integrated Development and Manufacturing
Organization (IDMO) dedicated to clinical and industrial-scale cell
therapy manufacturing, today announced that Kite, a Gilead Company,
will evaluate Cellares’ automated manufacturing platform, the Cell
Shuttle. The data generated in this proof-of-concept evaluation
will be utilized to assess viability of the Cell Shuttle as a
future manufacturing option for Kite.
“This agreement with Kite allows the unique capabilities of our
Cell Shuttle platform to be potentially utilized by Kite in the
future, and reinforces Cellares' position as a cell therapy
manufacturer with advanced automated technology," said Fabian
Gerlinghaus, CEO and Co-Founder of Cellares. "We aim to fully
automate all cell therapy manufacturing processes, moving us closer
to delivering CAR T-cell therapies for a wide range of autoimmune
diseases and cancers. We are honored to work with an industry
leader such as Kite, that already is serving patients worldwide
with two commercially approved cell therapies."
“Given that manufacturing is central to how we deliver CAR
T-cell therapies to physicians and patients, we are always
assessing what technologies could further enhance our best-in-class
manufacturing capabilities,” said Chris McDonald, Senior Vice
President and Global Head of Technical Operations, Kite. “We
welcome this opportunity to evaluate Cellares’ automation
production platform for how it potentially could help us reach even
more patients with our next-generation therapies.”
About Cellares
Cellares is the first Integrated Development and Manufacturing
Organization (IDMO) that takes an Industry 4.0 approach to mass
manufacturing the living drugs of the 21st century. The company is
both developing and operating integrated technologies for cell
therapy manufacturing to accelerate access to life-saving cell
therapies. The company’s Cell Shuttle integrates all the
technologies required for the manufacturing process in a flexible
and high-throughput platform that delivers true walk-away,
end-to-end automation. Cell Shuttles will be deployed in Cellares’
Smart Factories around the world to meet total patient demand for
cell therapies at a global scale. Partnering with Cellares enables
academics, biotechs, and pharma companies to accelerate drug
development and scale out manufacturing, lower process failure
rates, lower manufacturing costs, and meet global patient
demand.
The company is headquartered in South San Francisco, California
with its commercial-scale IDMO Smart Factory in Bridgewater, New
Jersey. The company is backed by world-class investors and has
raised over $355 million in financing.
For more information about Cellares, please visit
cellares.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627764162/en/
Cellares Contacts
Investors: ir@cellares.com
Media: pr@cellares.com